Fatima Cardoso

Citado por

	Total	Desde 2019
Citas	65306	39165
Índice h	103	78
Índice i10	319	239

9000

4500

2250

6750

200420052006200720082009201020112012201320142015201620172018201920202021202220232024174 221 362 612 922 1197 1385 1474 1758 1921 2265 2660 3089 3481 3591 3899 5185 6373 7220 7651 8476

Acceso público

Ver todo

101 artículos

11 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Christos SotiriouUniversité Libre de BruxellesDirección de correo verificada de bordet.be
E Rutgershoogleraar chirurgische oncologie UvADirección de correo verificada de nki.nl
Giuseppe VialeUniversità di Milano e Istituto Europeo di OncologiaDirección de correo verificada de ieo.it
Christine DesmedtKU LeuvenDirección de correo verificada de kuleuven.be
Elzbieta SenkusMedical University of GdanskDirección de correo verificada de gumed.edu.pl
Sherene LoiPeter MacCallum Cancer Centre, Melbourne, AustraliaDirección de correo verificada de petermac.org
Angelo Di LeoHospital of PratoDirección de correo verificada de uslcentro.toscana.it
Frederique Penault-LlorcaPU-PH anatomie et cytologie pathologiques, université Clermont AuvergneDirección de correo verificada de clermont.unicancer.fr
KONSTANTINOS TRYFONIDISMedical OncologyDirección de correo verificada de eortc.be
IT RUBIOCirujana, Universidad de NavarraDirección de correo verificada de unav.es
Peter A. FaschingFriedrich-Alexander UniversityDirección de correo verificada de uk-erlangen.de
Mauro DelorenziSIB Swiss Institute of BioinformaticsDirección de correo verificada de unil.ch
Marc BuyseChief Scientific Officer, IDDIDirección de correo verificada de iddi.com
Carsten DenkertProfessor of Pathology, Philipps-University Marburg, GermanyDirección de correo verificada de uni-marburg.de
Rebecca DentSenior Consultant, National Cancer Center Singapore; Professor, Duke-NUS Medical SchoolDirección de correo verificada de duke-nus.edu.sg
Liyi JiaMerck Research LaboratoriesDirección de correo verificada de merck.com
Sherko KümmelProfessor für Medizin, Kliniken Essen-Mitte, Wissenschaftlicher Mitarbeiter Charité BerlinDirección de correo verificada de kem-med.com
Lajos PusztaiYale School of MedicineDirección de correo verificada de yale.edu
Benjamin Haibe-KainsScientist (Principal Investigator), Princess Margaret Cancer Centre, University Health NetworkDirección de correo verificada de uhnresearch.ca
Suzette DelalogeInstitut Gustave RoussyDirección de correo verificada de gustaveroussy.fr

Seguir

Fatima Cardoso

Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal

Dirección de correo verificada de fundacaochampalimaud.pt

breast cancer guidelines new drugs


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013	4578	2013
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up F Cardoso, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, ... Annals of oncology 30 (8), 1194-1220, 2019	2689	2019
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ... Journal of the National Cancer Institute 98 (4), 262-272, 2006	2361	2006
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015	2346	2015
Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020	2329	2020
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up E Senkus, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, ... Annals of oncology 26, v8-v30, 2015	2112	2015
70-gene signature as an aid to treatment decisions in early-stage breast cancer F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ... New England Journal of Medicine 375 (8), 717-729, 2016	1995	2016
Current and future burden of breast cancer: Global statistics for 2020 and 2040 M Arnold, E Morgan, H Rumgay, A Mafra, D Singh, M Laversanne, ... The Breast 66, 15-23, 2022	1771	2022
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ... Journal of the National Cancer Institute 98 (17), 1183-1192, 2006	1541	2006
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study J Cortes, J O'Shaughnessy, D Loesch, JL Blum, LT Vahdat, K Petrakova, ... The Lancet 377 (9769), 914-923, 2011	1353	2011
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients E de Azambuja, F Cardoso, G de Castro, M Colozza, MS Mano, ... British journal of cancer 96 (10), 1504-1513, 2007	1345	2007
4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018	1312	2018
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017	1302	2017
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020	1194	2020
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ... Clinical cancer research 13 (11), 3207-3214, 2007	1098	2007
Extracellular vesicle and particle biomarkers define multiple human cancers A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ... Cell 182 (4), 1044-1061. e18, 2020	959	2020
3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017	925	2017
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F Andre, CH Barrios, ... The Breast 23 (5), 489-502, 2014	866	2014
Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022	845	2022
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up E Senkus, S Kyriakides, F Penault-Llorca, P Poortmans, A Thompson, ... Annals of oncology 24, vi7-vi23, 2013	717	2013

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores